18:40 , Aug 8, 2018 |  BC Innovations  |  Emerging Company Profile

Catching antibodies with polymers

Polyneuron Pharmaceuticals AG's glycopolymers act as decoys for the autoantibodies that drive autoimmune diseases, such as anti-MAG neuropathy, and are designed to be more effective and safer than other therapies. Polyneuron's Antibody-Catch platform generates glycopolymers...
15:56 , Apr 25, 2017 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease; neurology

INDICATION: Neuropathy Patient sample and mouse studies identified an IgM-binding glycopolymer that could help treat anti- MAG neuropathy, a peripheral neuropathy caused by anti-MAG IgM autoantibodies. Chemical synthesis and testing in patient serum samples of...
16:37 , Jan 11, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Stroke Mouse studies suggest inhibiting signaling between RTN4R , RTN4RL2 and their ligands could help treat white matter stroke. In a mouse model of the disease, white matter levels of three negative regulators of...
07:00 , Mar 19, 2015 |  BC Innovations  |  Product R&D

AAV for HIV

On top of the problem of creating an HIV vaccine against a rapidly mutating virus, immunologists have been stumped for many years by the fact that preventing access to CD4 - HIV's key entry point...
08:00 , Jan 13, 2014 |  BC Week In Review  |  Company News

General Electric, Thermo Fisher deal

General Electric's GE Healthcare unit will acquire three businesses from Thermo Fisher for about $1.1 billion. The businesses are Thermo Fisher's HyClone cell culture media and sera products; gene modulation technologies; and Sera-Mag magnetic beads...
01:28 , Jan 7, 2014 |  BC Extra  |  Company News

GE to acquire three Thermo Fisher businesses

The GE Healthcare unit of General Electric Co. (NYSE:GE) will acquire three businesses from Thermo Fisher Scientific Inc. (NYSE:TMO) for about $1.1 billion. The businesses are Thermo Fisher's HyClone cell culture media and sera products;...
07:00 , Sep 27, 2010 |  BioCentury  |  Emerging Company Profile

Axerion: Going beyond NOGO

While several companies are working on approaches to stimulating axonal regrowth for conditions caused or characterized by nerve damage, Axerion Therapeutics Inc. believes its NGR receptor decoys will more potently treat conditions such as acute...
07:00 , Jul 1, 2010 |  BC Innovations  |  Targets & Mechanisms

Neuraminidase for spinal cord injury

Researchers at The Johns Hopkins University School of Medicine have shown that treatment with a recombinant bacterial neuraminidase can promote the recovery of motor and autonomic function in a rat model of spinal cord contusion...
07:00 , May 27, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Spinal cord injury (SCI) Reticulon 4 (RTN4; NOGO-A; NOGO); myelin-associated glycoprotein (MAG); oligodendrocyte myelin glycoprotein (OMG; OMGP); reticulon 4 receptor (RTN4R; NGR) In vitro and...
08:00 , Jan 28, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Indication

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Herpes simplex virus (HSV) Myelin-associated glycoprotein (MAG); herpes simplex virus glycoprotein B (gB) A study in cell culture suggests that inhibiting interactions between HSV...